Pharmaceutical compounds

A compound or a salt thereof having the following general formula (I):

• A—B—C—N(O)2 (I)
• wherein:
• A =R-T1-, wherein
• R is the radical of a drug having the formula R—T1—Z or R—T1—OZ, wherein
• T1 is (CO), O, S, N or NR1c wherein
• R1c is H, C1-C5 alkyl or a free valance,
• Z is H or C1-C5 alky;
• and
• the drug having the formula R-T1-Z or R-T1-OZ is selected from the following classes:
• anti-inflammatory drugs:
• acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium salt, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamlc acid, meloxicam, mesalamine, naproxen, niflumic acid, olsalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, tolmetin, and zomepirac;
• analgesic drugs:
• acetaminophen, acetylsalicylsallcylic acid, benoxaprofen, buprenorphine, butorphanol, capsaicin, diacereine, dihydrocodeine, ethylmorphine, eugenol, phenylbutazone, meptazinol, morphine, nalbuphine, pentazocine, thiorphan, tramadol, actarit;
• bronchodilators drugs:
• albuterol, carbuterol, clenbuterol, dyphylline, etofylline, fenoterol, metaproterenol, pirbuterol, salmeterol, and terbutaline;
• antihistaminic drugs:
• cetirizine, levocabastine, and terfenadine;
• ACE-inhibitors:
• captopril, enalapril, lisinopril, ramipril;
• beta blockers:
• alprenolol, atenolol, bupranolol, labetalol, metipranolol, metoprolol, pindolol, propranolol, timolol;
• antithrombotic and vasoactive drugs:
• acetorfan, argatroban, clopidogrel, dalteparin, dipyridamole, enoxaparin, heparin, iloprost, midodrine, ozagrel, phenylpropanolamine, trifusal;
• antidiabetic drugs:
• nicotinamide, tolrestat;
• antiulcer drugs:
• cimetidine, omeprazole and pantoprazole;
• antiviral drugs:
• acyclovir, famciclovir, ganciclovir, penciclovir, ribavirin, vidarabine, zidovudine;
• B =TB-X2-TBl-wherein
• TB and TBl are equal or different,
• TB is (CO) when T1 is O, S, N, or NR1C, wherein R1C is as above defined, or
• TB is O, S, N, or NR1C, wherein R1C is as above defined, when T1 is (CO);
• TBl is (CO), O, S, N, or NR1C, wherein R1C is as above defined;
• X2 is a bivalent bridging group having the formula Z′-TB-X2-TBl-Z″, in which Z′, Z″ are independently H or OH, TB, X2, and TBl are as above defined, and Z′-B-X2-TBl-Z″ is selected from the following aminoacids:
• L-carnosine (Cl), penicillamine (CV), N-acetylpenicillamine (CVI), cysteine (CVII), N-acetylcysteine (CVIII):
• C is a bivalent radical -Tc-Y— wherein
• TC is (CO) when TBl is O, S, or NR1C,
• TC is O, S, or NR1C when TB1 is (CO), R1C being as above defined,
• Y is a linear or branched C1-C20 alkylenoxy group.